<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1351">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05143567</url>
  </required_header>
  <id_info>
    <org_study_id>11.10.2021</org_study_id>
    <nct_id>NCT05143567</nct_id>
  </id_info>
  <brief_title>Hemostasis and Inflammation in COVI19 Patients With Venous and Arterial Thrombotic Complications</brief_title>
  <official_title>Comprehensive Assessment of the Hemostasis and Inflammation in Patients With Venous and Arterial Thrombotic Complications in Treatment of New Coronaviral Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ryazan State Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ryazan State Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed at assessing the role of the activity of high-risk markers of thrombotic&#xD;
      events (MCP-1, MIP1α, IP-10, phosphatedylserine, calreticulin) on the development of&#xD;
      thrombotic complications in patients with COVID -19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is aimed at assessing the role of the activity of high-risk markers for thrombotic&#xD;
      events (monocytic chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1α&#xD;
      (MIP1α), interferon-induced gamma protein-10 (IP-10), platelet apoptosis markers&#xD;
      (phosphatedylserine, calreticulin) on the development of thrombotic complications in patients&#xD;
      with COVID -19.&#xD;
&#xD;
      The study will include 150 patients of similar age, gender, and ethnicity, and they will be&#xD;
      divided into three groups: Group I: 50 patients with confirmed coronavirus infection without&#xD;
      thrombotic complications; Group II: 50 patients with confirmed coronavirus infection with&#xD;
      thrombotic complications confirmed by ultrasonography without the use of pharmacomechanical&#xD;
      prophylaxis of VTE; Group III: 50 patients with confirmed coronavirus infection with&#xD;
      ultrasound-confirmed thrombosis of the deep and saphenous veins of the lower extremities&#xD;
      using pharmacomechanical prophylaxis of VTE&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-label cohort longitudinal study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mortality</measure>
    <time_frame>one year</time_frame>
    <description>lethal outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>venous thrombosis or pulmonary embolism</measure>
    <time_frame>one year</time_frame>
    <description>a VTE event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>arterial thrombosis</measure>
    <time_frame>one year</time_frame>
    <description>thrombosis of main arteries of the extremities or myocardial infarction or stroke</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>covid19</condition>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>patients with COVID19 without thrombotic complications</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group I: 50 patients with confirmed coronavirus infection without thrombotic complications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with COVID19 and VTE who receive pharmacological prophylaxis of VTE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group II: 50 patients with confirmed coronavirus infection with thrombotic complications confirmed by ultrasonography with pharmacological prophylaxis of VTE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with COVID19 and VTE who receive pharmacomechanical prophylaxis of VTE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group III: 50 patients with confirmed coronavirus infection with ultrasound-confirmed thrombosis of the deep and saphenous veins of the lower extremities using pharmacomechanical prophylaxis of VTE.&#xD;
Each patient in each group receives a different anticoagulation option. Depending on the type of anticoagulant treatment, each group will be divided into subgroups:&#xD;
Subgroup A - patients receive UFH for the prevention or treatment of VTE Subgroup B - patients receive LMWH for the prevention or treatment of VTE Subgroup C - patients receive oral anticoagulants for the prevention or treatment of VTE</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard of care anticoagulation alone or in combination with elastic compression</intervention_name>
    <description>standard of care anticoagulation alone or in combination with elastic compression</description>
    <arm_group_label>patients with COVID19 and VTE who receive pharmacological prophylaxis of VTE</arm_group_label>
    <arm_group_label>patients with COVID19 and VTE who receive pharmacomechanical prophylaxis of VTE</arm_group_label>
    <arm_group_label>patients with COVID19 without thrombotic complications</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  men or women over 18 years of age with a new coronavirus infection, confirmed by&#xD;
             polymerase chain reaction (PCR) studies and chest CT.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  men or women under 18 years of age; active cancer or a remission period of less than 5&#xD;
             years; decompensated somatic pathology; pregnancy or breastfeeding in women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Igor Suchkov, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Ryazan State Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Igor Suchkov, MD, PhD</last_name>
    <phone>+7(4912) 97-18-01</phone>
    <email>suchkov_med@mail.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ryazan State Medical University</name>
      <address>
        <city>Ryazan'</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrey Agapov, MD, PhD</last_name>
      <phone>+7(4912) 97-18-01</phone>
      <email>agapchik2008@yandex.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 20, 2021</study_first_submitted>
  <study_first_submitted_qc>November 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2021</study_first_posted>
  <last_update_submitted>November 20, 2021</last_update_submitted>
  <last_update_submitted_qc>November 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ryazan State Medical University</investigator_affiliation>
    <investigator_full_name>Agapov Andrey Borisovich</investigator_full_name>
    <investigator_title>Post-doctoral researcher</investigator_title>
  </responsible_party>
  <keyword>venous thromboembolism</keyword>
  <keyword>VTE</keyword>
  <keyword>thrombotic events</keyword>
  <keyword>coronavirus</keyword>
  <keyword>covid19</keyword>
  <keyword>hemostasis</keyword>
  <keyword>platelet function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

